Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.41 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP51A1 | Q16850 | 3/20 | 0.37 |
| ▸ | FABP4 | P15090 | 1/20 | 0.32 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KMO | O15229 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12702313 | 0.74 | KCNH2 (0.42) | KCNH2CACNA1FCACNA1DSLC6A3CACNA1S | |
| SCHEMBL14907396 | 0.73 | PPARA (0.42) | KCNH2CYP51A1MEN1KMT2A | |
| SCHEMBL12702522 | 0.72 | KCNH2 (0.36) | KCNH2CACNA1FCACNA1DSLC6A3CACNA1S | |
| SCHEMBL30463341 | 0.71 | MYC (0.40) | LMNACYP1A2CYP2D6MAPK1HTT | |
| SCHEMBL14907392 | 0.69 | FABP4 (0.40) | CYP1A2CYP2D6FABP4FABP5MAPK1 | |
| SCHEMBL12702319 | 0.68 | KCNH2 (0.38) | KCNH2CACNA1FCACNA1DSLC6A3CACNA1S | |
| SCHEMBL14907388 | 0.67 | DHODH (0.46) | CYP1A2CYP2D6MEN1KMT2AKMO | |
| SCHEMBL14907446 | 0.66 | DHODH (0.46) | CYP1A2CYP2D6MEN1KMT2AKMO | |
| SCHEMBL14907385 | 0.64 | PPARA (0.45) | CYP1A2CYP2D6MAPK1MEN1KMT2A | |
| SCHEMBL13017351 | 0.63 | CRHR1 (0.42) | KCNH2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10835524-B2 | Compositions for the treatment of pancreatic cancer and uses thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2020-11-17 | — | — | US | claimed |
| US-10835524-B2 | Compositions for the treatment of pancreatic cancer and uses thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2020-11-17 | — | — | US | disclosed |
| US-20180177776-A1 | COMPOSITIONS FOR THE TREATMENT OF CANCER AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INCORPORATED (US) | 2018-06-28 | — | — | US | disclosed |
| WO-2016209688-A1 | COMPOSITIONS FOR THE TREATMENT OF CANCER AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2016-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10835524-B2 | Compositions for the treatment of pancreatic cancer and uses thereof | PIK3CA, MTOR, PIK3CD | KCNH2 4461/4885CACNA1F 4766/4885CACNA1D 4748/4885 |
| US-20180177776-A1 | COMPOSITIONS FOR THE TREATMENT OF CANCER AND USES THEREOF | PIK3CA, MTOR, PIK3CD | KCNH2 4605/4885CACNA1F 4793/4885CACNA1D 4792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.